Real-world incidence of inflammatory bowel disease among patients with other chronic inflammatory diseases treated with interleukin-17a or phosphodiesterase 4 inhibitors.

CONCLUSIONS: Anti-IL-17a treatment was associated with a nearly 3-fold higher risk of IBD in CID patients. Treatment decisions for patients with CIDs should take into account the risk of developing of IBD. PMID: 31106607 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31106607?dopt=Abstract

Source: Current Medical Research and Opinion - May 22, 2019 Category: Research Tags: Curr Med Res Opin Source Type: research